Colgate-Palmolive (CL) Stock Forecast & Price Target

Colgate-Palmolive is well positioned for a constructive outlook because its international business has consistently delivered mid-to-high single-digit organic growth, with emerging markets providing strong momentum and Europe showing that a disciplined two-brand strategy can unlock roughly +300 bps of toothpaste share gains since 2016 while supporting premiumization and margin expansion. The company’s Hill’s Pet Nutrition franchise adds another high-quality growth engine, while management’s Global Growth and Efficiency Program, with expected annual savings of up to $500–575 million and an after-tax return greater than 30%, provides a meaningful earnings lever to offset cost pressure and support the expected +3-4% organic sales growth and +5-6% EPS growth in 2026-28. Although North America has been a drag, the self-inflicted issues are identifiable and the European playbook is proven, so stabilization starting in 1Q27 and North America delivery of +1% in 2027 could materially improve the company’s overall growth algorithm.

Colgate-Palmolive is facing a fundamentally weaker U.S. franchise because years of self-inflicted execution errors—higher pricing alongside reduced promotions, channel exits, and underinvestment in North America marketing—created a vacuum that well-funded competitors P&G and Haleon exploited, driving share losses in whitening and premium therapeutics. Haleon’s dentist-backed Sensodyne and Parodontax portfolios have built a structurally superior clinical position that Colgate has not matched, leaving Colgate Total with a diluted value proposition after the 2017-2018 triclosan-to-stannous fluoride reformulation and forcing the company to rely on a 2025 relaunch and incremental fixes rather than a clear category-defining innovation. Although Colgate’s international business has compounded at mid-to-high single-digit organic growth and Hill’s remains a meaningful contributor, North America has posted negative organic sales in the majority of the past two years and underperformed HPC peers by about 250 bps over the last eight quarters, so the stock’s upside remains constrained until the U.S. business stabilizes and regains durable share.